

Measurement Period for Denominators and Numerators for the 2026 Adult Core Set Measures

Measure	2026 Measurement Period ^a		
	Denominator ^b	Numerator	Continuous Enrollment Period
AAB-AD: Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis: Age 18 and Older	<p>Intake Period: July 1, 2024 – June 30, 2025</p> <p>Negative medication history review: June 1, 2024 – June 30, 2025 (30 days prior to the episode date)</p> <p>Negative comorbid condition history: July 1, 2023 – June 30, 2025 (365 days prior to and including the episode date [366 days total])</p>	July 1, 2024 – July 3, 2025 (Episode date through three days after episode date)	June 1, 2024 – July 3, 2025 (30 days prior to episode date through three days after episode date [34 total days])
AIS-AD: Adult Immunization Status	January 1, 2025 – December 31, 2025	<p>Influenza Rate: July 1, 2024 – June 30, 2025</p> <p>Td/Tdap Rate: January 1, 2016 – December 31, 2025</p> <p>Zoster Rate: Two doses at least 28 days apart from October 20, 2017 – December 31, 2025</p> <p>Pneumococcal Rate: At least one dose from the beneficiary's 19th birthday – December 31, 2025</p> <p>Hepatitis B Rate (one of the following):</p> <ul style="list-style-type: none"> Three doses of the childhood hepatitis B vaccine with different dates of service on or before the beneficiary's 19th birthday Hepatitis B vaccine series from beneficiary's 19th birthday through December 31, 2025 	January 1, 2025 – December 31, 2025 ^c

Measure	2026 Measurement Period ^a		
	Denominator ^b	Numerator	Continuous Enrollment Period
AIS-AD: Adult Immunization Status (continued)		<ul style="list-style-type: none"> Hepatitis B surface antigen, hepatitis B surface antibody or total antibody to hepatitis B core antigen test, with a positive result any time on or before December 31, 2025 History of hepatitis B illness any time on or before December 31, 2025 <p>All rates: contraindication due to the specified vaccine any time on or before December 31, 2025</p>	
AMR-AD: Asthma Medication Ratio: Ages 19 to 64	January 1, 2024 – December 31, 2025	January 1, 2025 – December 31, 2025	January 1, 2024 – December 31, 2025 ^d
BCS-AD: Breast Cancer Screening	January 1, 2025 – December 31, 2025	October 1, 2023 – December 31, 2025	October 1, 2023 – December 31, 2025 ^e
CBP-AD: Controlling High Blood Pressure	January 1, 2024 – June 30, 2025	January 1, 2025 – December 31, 2025 ^f	January 1, 2025 – December 31, 2025 ^c
CCP-AD: Contraceptive Care – Postpartum Women Ages 21 to 44	Delivery Date: January 1, 2025 – September 30, 2025	<p>3-Day Rates: January 1, 2025 – October 3, 2025 (Delivery date through 3 days after delivery date)^g</p> <p>90-Day Rates: January 1, 2025 – December 31, 2025 (Delivery date through 90 days after delivery date)^g</p>	January 1, 2025 – December 31, 2025 (Delivery date through 90 days after delivery date)
CCS-AD: Cervical Cancer Screening	January 1, 2025 – December 31, 2025	<p>Ages 24–64: January 1, 2023 – December 31, 2025</p> <p>Ages 30–64: January 1, 2021 – December 31, 2025</p>	January 1, 2025 – December 31, 2025 ^d
CCW-AD: Contraceptive Care – All Women Ages 21 to 44	January 1, 2025 – December 31, 2025	January 1, 2025 – December 31, 2025 ^g	January 1, 2025 – December 31, 2025 ^c
CDF-AD: Screening for Depression and Follow-Up Plan: Age 18 and Older	January 1, 2025 – December 31, 2025	January 1, 2025 – December 31, 2025	None

Measure	2026 Measurement Period ^a		
	Denominator ^b	Numerator	Continuous Enrollment Period
CHL-AD: Chlamydia Screening: Ages 21 to 24	January 1, 2025 – December 31, 2025	January 1, 2025 – December 31, 2025	January 1, 2025 – December 31, 2025 ^c
COB-AD: Concurrent Use of Opioids and Benzodiazepines	Index Prescription Start Date (IPSD): January 1, 2025 – December 2, 2025	January 1, 2025 – December 31, 2025	January 1, 2025 – December 31, 2025 ^h
COL-AD: Colorectal Cancer Screening	January 1, 2025 – December 31, 2025	Fecal occult blood test: January 1, 2025 – December 31, 2025 Stool DNA (sDNA) with fecal immunochemical (FIT) test: January 1, 2023 – December 31, 2025 Flexible sigmoidoscopy or CT colonography: January 1, 2021 – December 31, 2025 Colonoscopy: January 1, 2016 – December 31, 2025	January 1, 2024 – December 31, 2025 ^d
CPA-AD: Consumer Assessment of Healthcare Providers and Systems (CAHPS®) Health Plan Survey 5.1H, Adult Version (Medicaid)	Not applicable (varies by survey question; most questions reference “the last 6 months”)	Not applicable (varies by survey question; most questions reference “the last 6 months”)	July 1, 2025 – December 31, 2025 ⁱ
EDV-AD: Ambulatory Care Sensitive Emergency Department Visits for Non-Traumatic Dental Conditions in Adults	January 1, 2025 – December 31, 2025	January 1, 2025 – December 31, 2025	None
FUA-AD: Follow-Up After Emergency Department Visit for Substance Use: Age 18 and Older	Emergency department (ED) visit date: January 1, 2025 – December 1, 2025	7-Day Follow-up: January 1, 2025 – December 8, 2025 (ED visit date through 7 days after visit date) 30-Day Follow-up: January 1, 2025 – December 31, 2025 (ED visit date through 30 days after visit date)	January 1, 2025 – December 31, 2025 (ED visit date through 30 days after visit date)

Measure	2026 Measurement Period ^a		
	Denominator ^b	Numerator	Continuous Enrollment Period
FUH-AD: Follow-Up After Hospitalization for Mental Illness: Age 18 and Older	Discharge date: January 1, 2025 – December 1, 2025	7-Day Follow-up: January 2, 2025 – December 8, 2025 (7 days after discharge date) 30-Day Follow-up: January 2, 2025 – December 31, 2025 (30 days after discharge date)	January 1, 2025 – December 31, 2025 (30 days after discharge date)
FUM-AD: Follow-Up After Emergency Department Visit for Mental Illness: Age 18 and Older	ED visit date: January 1, 2025 – December 1, 2025	7-Day Follow-up: January 1, 2025 – December 8, 2025 (ED visit date through 7 days after visit date) 30-Day Follow-up: January 1, 2025 – December 31, 2025 (ED visit date through 30 days after visit date)	January 1, 2025 – December 31, 2025 (ED visit date through 30 days after visit date)
GSD-AD: Glycemic Status Assessment for Patients with Diabetes	January 1, 2025 – December 31, 2025 Diabetes diagnosis: January 1, 2024 – December 31, 2025	January 1, 2025 – December 31, 2025	January 1, 2025 – December 31, 2025 ^c
HPCMI-AD: Diabetes Care for People With Serious Mental Illness: Glycemic Status >9.0%	January 1, 2025 – December 31, 2025 Diabetes diagnosis: January 1, 2024 – December 31, 2025	January 1, 2025 – December 31, 2025	January 1, 2025– December 31, 2025 ^c
HVL-AD: HIV Viral Load Suppression	January 1, 2025 – December 31, 2025	January 1, 2025 – December 31, 2025	None
IET-AD: Initiation and Engagement of Substance Use Disorder Treatment	Substance use disorder (SUD) episode date: November 15, 2024 – November 14, 2025 Negative SUD diagnosis and medication history review: May 5, 2024 – November 14, 2025 (194 days prior to the SUD episode date)	Initiation of SUD Treatment: November 15, 2024 – November 28, 2025 (Within 14 days of the SUD episode date) ^j Engagement of SUD Treatment: November 16, 2024 – December 31, 2025 (Day after initiation encounter through 34 days after the initiation event) ^j	May 5, 2024 – December 31, 2025 (194 days prior to the SUD episode date through 47 days after the SUD episode date)
LRCD-AD: Low-Risk Cesarean Delivery: Age 20 and Older	Birth date: January 1, 2025 – December 31, 2025	January 1, 2025 – December 31, 2025	None

Measure	2026 Measurement Period ^a		
	Denominator ^b	Numerator	Continuous Enrollment Period
MSC-AD: Medical Assistance with Smoking and Tobacco Use Cessation	Not applicable (includes survey respondents who currently smoke every day or some days)	Not applicable (references “the last 6 months”)	Year 1: July 1, 2024 – December 31, 2024 ⁱ Year 2: July 1, 2025 – December 31, 2025 ⁱ
OEVP-AD: Oral Evaluation During Pregnancy: Ages 21 to 44	Delivery date: January 1, 2025 – December 31, 2025	April 6, 2024 – December 30, 2025 (270 days prior to the delivery date)	July 5, 2024 – December 31, 2025 (180 days prior to delivery through the delivery date)
OUD-AD: Use of Pharmacotherapy for Opioid Use Disorder	January 1, 2025 – December 31, 2025	January 1, 2025 – December 31, 2025	January 1, 2025 – December 31, 2025
PCR-AD: Plan All-Cause Readmissions	Index hospital stay (IHS) discharge date: January 1, 2025 – December 1, 2025	January 3, 2025 – December 31, 2025 (2 days through 30 days following IHS discharge date)	January 1, 2024 – December 31, 2025 (365 days prior to and including IHS discharge date through 30 days after the IHS discharge date) ^k
PDS-AD: Postpartum Depression Screening and Follow-Up: Age 21 and Older	Delivery date: September 8, 2024 – September 7, 2025	Depression Screening: September 15, 2024 – November 30, 2025 (7 to 84 days following the delivery date) Follow-up on Positive Screen: <ul style="list-style-type: none"> September 15, 2024 – December 31, 2025 (On or up to 30 days after the date of the first positive screen [31 total days]) or September 15, 2024 – November 30, 2025 (Documentation of additional depression screening on the same day as a positive screen) 	September 8, 2024 – November 6, 2025 (Delivery date through 60 days following the delivery date)

Measure	2026 Measurement Period ^a		
	Denominator ^b	Numerator	Continuous Enrollment Period
PND-AD: Prenatal Depression Screening and Follow-Up: Age 21 and Older	Delivery date: January 1, 2025 – December 31, 2025	Depression Screening: <ul style="list-style-type: none"> Delivery date January 1, 2025 – December 1, 2025: Screening from pregnancy start date through the delivery date Delivery date December 2, 2025 – December 31, 2025: Screening from pregnancy start date through December 1, 2025 Follow-Up on Positive Screen: On or up to 30 days after the date of the first positive screen [31 total days]	December 4, 2024 – December 31, 2025 (28 days prior to the delivery date through the delivery date)
PPC2-AD: Prenatal and Postpartum Care: Age 21 and Older	Delivery date: October 8, 2024 – October 7, 2025	Timeliness of Prenatal Care: Visit in the first trimester: January 2, 2024 – April 14, 2025 (176 to 280 days prior to delivery) Note: Women who were not continuously enrolled (with no gaps) from at least 219 days before delivery through 60 days after delivery must have a prenatal visit any time during the period that begins 280 days prior to delivery and ends 42 days after their enrollment start date (not including visits on or after the date of delivery). Postpartum Care: October 15, 2024 – December 30, 2025 (7 to 84 days after delivery date)	August 26, 2024 – December 6, 2025 (43 days prior to delivery date through 60 days after delivery date)
PQI01-AD: PQI 01: Diabetes Short-Term Complications Admission Rate	January 1, 2025 – December 31, 2025	January 1, 2025 – December 31, 2025	None
PQI05-AD: PQI 05: Chronic Obstructive Pulmonary Disease (COPD) or Asthma in Older Adults Admission Rate	January 1, 2025 – December 31, 2025	January 1, 2025 – December 31, 2025	None

Measure	2026 Measurement Period ^a		
	Denominator ^b	Numerator	Continuous Enrollment Period
PQI08-AD: PQI 08: Heart Failure Admission Rate	January 1, 2025 – December 31, 2025	January 1, 2025 – December 31, 2025	None
PQI15-AD: PQI 15: Asthma in Younger Adults Admission Rate	January 1, 2025 – December 31, 2025	January 1, 2025 – December 31, 2025	None
PRS-AD: Prenatal Immunization Status: Age 21 and Older	Delivery date: January 1, 2025– December 31, 2025	Influenza Rate: July 1, 2024 – December 31, 2025 (or anaphylaxis due to the influenza vaccine on or before the delivery date) Tdap Rate: March 6, 2024 - December 31, 2025 (During the pregnancy [including on the delivery date] or anaphylaxis or encephalitis due to the Tdap vaccine on or before the delivery date)	December 4, 2024 – December 31, 2025 (28 days prior to the delivery date through the delivery date)
SAA-AD: Adherence to Antipsychotic Medications for Individuals with Schizophrenia	Index prescription start date (IPSD): January 1, 2025 – December 31, 2025	January 1, 2025 – December 31, 2025 (IPSD through December 31, 2025)	January 1, 2025 – December 31, 2025 ^c
SSD-AD: Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications	January 1, 2025 – December 31, 2025 Diabetes diagnosis: January 1, 2024 – December 31, 2025	January 1, 2025 – December 31, 2025	January 1, 2025 – December 31, 2025 ^c

^a For some measures, the measurement period for the numerator, denominator, or continuous enrollment period varies depending on a specified date for each beneficiary (such as beneficiary birthdates, prescription or treatment start dates, and discharge dates). For these measures, two ranges are shown. The first date range identifies the full range of possible dates that states will need to use to calculate the measure for all measure-eligible beneficiaries. The text in parentheses describes the measurement period that should be used for each eligible beneficiary.

^b When reporting each measure to CMS, states should indicate whether they defined the measurement period according to Core Set specifications. For many measures, this date range corresponds to calendar year 2025 (January 1, 2025 – December 31, 2025). Some measures also require states to review utilization or enrollment prior to this period to identify the measure eligible population. For example, the IET-AD measure instructs states to identify beneficiaries with SUD episode start dates that started November 15, 2024 through November 14, 2025 (the first date range). However, states will also need to review a beneficiary's SUD diagnosis and medication history for 194 days prior to the SUD episode date to confirm that the patient had no claims/encounters with a diagnosis of SUD (the second date range). States that followed the 2026 Adult Core Set specifications (that is, calculated the denominator using SUD episode start dates from November 2024 through November 2025) should select "Yes, our state adhered to Core Set specifications in defining the measurement period for calculating this measure." States that used a different date range, should answer "No" to this question and provide the Start Date and End Date they used to identify the Denominator (based on the first date range and not the look-back period). States should note variations from any measurement period (numerator, denominator, continuous enrollment) in the "Variations from Measurement Specifications" section.

- ^c No more than one gap in enrollment of up to 45 days during the continuous enrollment period.
- ^d No more than one gap in enrollment of up to 45 days during each year of the continuous enrollment period.
- ^e No more than one gap in enrollment of up to 45 days for each full calendar year of continuous enrollment. No gaps are allowed during the first three months of the continuous enrollment period (October 1, 2023 – December 31, 2023)
- ^f Blood pressure reading must occur on or after the date of the second diagnosis of hypertension.
- ^g Applies to both the Most or Moderately Effective Contraception rate and Long-Acting Reversible Contraception (LARC) rate.
- ^h No more than one gap in continuous enrollment of up to 31 days during the measurement year.
- ⁱ No more than one gap in enrollment of up to 45 days during the last six months of the measurement year. In addition, the beneficiary must be enrolled in Medicaid or CHIP at the time of the survey.
- ^j Applies to all rates: Alcohol use disorder, Opioid use disorder, Other substance use disorder, and Total.
- ^k No more than one gap in enrollment of up to 45 days during the 365 days prior to the index discharge date and no gap during the 30 days following the index discharge date.